Compare DexCom, Inc. (DXCM) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Macy's Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Macy's Inc trades at $22.88 (market cap $5.95B). The key difference: DexCom, Inc. is far larger — about 5.3× Macy's Inc's market cap, and Macy's Inc pays a 3.36% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Macy's Inc for 58 Days on average.
| DXCM | M | |
|---|---|---|
Market Cap | $31.81B | $5.95B |
Volume | 2,861,821 | 11,329,747 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $26.21 |
52-Week Low | $54.84 | $16.51 |
Typical Hold Time | 62 Days | 58 Days |
Enterprise Value | $31.26B | $9.75B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Macy's stock trades at $22.79, up 1.47% with a bullish technical signal and strong valuation metrics including a P/E of 8.35 and P/S of 0.27. The company has beaten earnings estimates for three consecutive quarters and maintains a 3.5% dividend yield. Recent 'Bold New Chapter' strategy initiatives are showing traction with improved sales and operational metrics.
The stock offers attractive value with upside to the $24.25 consensus target, though Q3 earnings risk and retail sector headwinds remain concerns. Positive cash flow generation and debt reduction support the dividend, while digital transformation efforts provide growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
